

Thursday 11 April, 2019

17:30-19:00 Opening Session
Key Note Lectures and Discussion – Microbiome

19:00-20:00 Welcome Reception

Friday 12 April, 2019

08:30-09:15 Plenary | Key Note Lecture

08:30-09:00 Diabetes prevention and early treatment:
09:00-09:15 Discussion

09:15-10:45 Session 1 | Diabetes

Is HbA1c still a valid target for diabetes treatment?
09:15-09:20 Case Presentation
09:20-09:30 Yes:
09:30-09:40 No:
09:40-09:45 Case Presentation
09:45-10:00 Discussion
Prevention of cardiac events in primary prevention: Should we use SGLT2 or GLP1?
10:00-10:05 Case Presentation
10:05-10:15 Yes
10:15-10:25 No
10:25-10:30 Case Presentation
10:30-10:45 Discussion

Session 2 | Hypertension and Diabetes

Should we aim at blood pressure <130 in diabetic subjects?
Case Presentation
Yes
No
Case Presentation
Discussion
Should SGLT2i be considered drugs for cardiologists?
Case Presentation
Yes:
No:
Case Presentation
Discussion

10:45-11:15 VISIT EXHIBITS & COFFEE BREAK

11:00-12:30	Session 3 Diabetes	Session 4 Obesity
	Should we treat NAFLD/NASH pharmacologically?	Is obesity a disease?
11:15-11:20	Case Presentation	Case Presentation
11:20-11:30	Yes	Yes
11:30-11:40	No	No
11:45-11:45	Case Presentation	Case Presentation
11:45-12:00	Discussion	Discussion
	Are biosimilar insulins equal to originators?	Should we consider metabolic bariatric surgery at the early diagnosis of diabetes?
12:00-12:05	Case Presentation	Case Presentation
12:05-12:15	Yes	Yes:
12:15-12:25	No	No:
12:25-12:30	Case Presentation	Case Presentation
12:30-12:45	Discussion	Discussion
12:45-13:15	VISIT EXHIBITS & LUNCH	
13:15-14:15	Industry Sponsored Symposium	Industry Sponsored Symposium
14:15-15:45	Session 5 Diabetes	Session 6 Hypertension
	Is there a cause-effect relationship between amputation and use of SGLT2i?	Should we constantly monitor 24 B/P in patients with hypertension?
14:15-14:20	Case Presentation	Case Presentation
14:20-14:30	Yes:	Yes
14:30-14:40	No:	No
14:40-14:45	Case Presentation	Case Presentation
14:45-15:00	Discussion	Discussion
	Cancer morbidity and Mortality: Should metformin be given to every diabetic person?	Volume overload is the main mechanism of resistant hypertension?
15:00-15:05	Case Presentation	Case Presentation
15:05-15:15	Yes:	Yes
15:15-15:25	No	No
15:25-15:30	Case Presentation	Case Presentation
15:30-15:45	Discussion	Discussion

15:45-16:00	VISIT EXHIBITS & COFFEE BREAK	
16:00-17:30	Session 7 Diabetes	Session 8 Obesity
	Should we change the A1C target in newly diagnosed patients?	Does non bariatric reduction in weight improve CVO in T2D patients?
16:00-16:05	Case Presentation	Case Presentation
16:05-16:15	Yes	Yes
16:15-16:25	No	No
16:25-16:30	Discussion	Discussion
16:30-16:45	Case Presentation	Case Presentation
	Should we change the A1C target to patient with long disease duration?	Should we reduce weight in elderly T2D patients?
16:45-16:50	Case Presentation	Case Presentation
16:50-17:00	Yes	Yes
17:00-17:10	No	No
17:10-17:15	Case Presentation	Case Presentation
17:15-17:30	Discussion	Discussion

Saturday 13 April, 2019		
08:30-09:15	Plenary Key Note Lecture	
08:30-09:00	New guidelines in diabetes:	
09:00-09:15	Discussion	
09:15-10:45	Session 9 Diabetes	Session 10 Hypertension
	Is beta-cell preservation feasible in type 2 diabetes?	TBC
09:15-09:20	Case Presentation	Case Presentation
09:20-09:30	Yes	Yes
09:30-09:40	No	No
09:40-09:45	Case Presentation	Case Presentation
09:45-10:00	Discussion	Discussion
	Can we choose antidiabetic drugs on the basis of expected adherence?	Is sodium restriction effective for lowering blood pressure?
10:00-10:05	Case Presentation	Case Presentation
10:05-10:15	Yes	Yes
10:15-10:25	No	No
10:25-10:30	Case Presentation	Case Presentation
10:30-10:45	Discussion	Discussion
10:45-11:15	VISIT EXHIBITS & COFFEE BREAK	

11:15-12:45	Session 11 Diabetes	Session 12 Obesity
	Should we turn to new therapies in most T2D despite the cost?	Is LDL still the best lipid predictor for cardiovascular patients?
11:15-11:20	Case Presentation	Case Presentation
11:20-11:30	Yes	Yes
11:30-11:40	No	No
11:40-11:45	Case Presentation	Case Presentation
11:45-12:00	Discussion	Discussion
	Is insulin still the best injectable therapy?	Should we use anti-obesity drugs on top of glucose lowering agents in T2D patients?
12:00-12:05	Case Presentation	Case Presentation
12:05-12:15	Yes: Geremia Bolli , Italy	Yes
12:15-12:25	No	No
12:25-12:30	Case Presentation	Case Presentation
12:30-12:45	Discussion	Discussion
12:45-13:15	VISIT EXHIBITS & LUNCH	
13:15-14:15	Industry Sponsored Symposium	Industry Sponsored Symposium
14:15-15:45	Session 13 Young Investigators Present Controversial Cases	Session 14 Hypertension
		Do GLP1RAs have an effect on microvascular complications independent of their glucose lowering action?
14:15-14:20		Case Presentation
14:20-14:30		Yes
14:30-14:40		No
14:40-14:45		Case Presentation
14:45-15:00		Discussion
		Should we change the definition of hypertension?
15:00-15:05		Case Presentation
15:05-15:15		Yes
15:15-15:25		No
15:25-15:30		Case Presentation
15:30-15:45		Discussion

15:45-16:00		VISIT EXHIBITS & COFFEE BREAK	
16:00-17:30		Session 15 Diabetes	Session 16 Obesity
	Has pancreatic islet transplantation failed clinical expectations?		Will dual agonists (GLP1/Glucagon) provide the pharmacologic treatment for obesity and diabetes?
16:00-16:05	Case Presentation		Case Presentation
16:05-16:15	Yes		Yes
16:15-16:25	No		No
16:25-16:30	Case Presentation		Case Presentation
16:30-16:45	Discussion		Discussion
	TBC		Should we prefer anti-diabetic weight lowering drugs?
16:45-16:50	Case Presentation		Case Presentation
16:50-17:00	Yes		Yes
17:00-17:10	No		No
17:10-17:15	Case Presentation		Case Presentation
17:15-17:30	Discussion		Discussion